Insulin degludec/insulin aspart

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[3] It contains insulin degludec and insulin aspart.[3] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[3]

Insulin degludec/insulin aspart
Combination of
Insulin degludecLong-acting human insulin analog
Insulin aspartFast-acting human insulin analog
Clinical data
Trade namesRyzodeg
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) [2]

for injection

  • EU: Rx-only [3]
Identifiers
KEGG

The most frequently reported side effect is hypoglycemia (low blood glucose levels).[3]

It was approved for medical use in the European Union in January 2013,[3] and in Australia in November 2017.[2]

Medical uses

Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[3]

Insulin degludec and insulin aspart are slightly different from human insulin.[3] The differences mean that insulin degludec is absorbed more slowly by the body.[3] This means it has a long duration of action.[3] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[3]

References
  1. "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
  2. "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.
  3. "Ryzodeg EPAR". European Medicines Agency (EMA). Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.